Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)

Kim, Ji Hyun; Lee, Dong-Eun; Lee, Yumi; Ha, Hyeong In; Chang, Yoon Jung; Chang, Suk-Joon; Park, Sang-Yoon; Lim, Myong Cheol

doi:10.3802/jgo.2022.33.e54

Cited by 22 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conventional intravenous chemotherapy is ineffective in killing and removing residual lesions and free tumor cells, which is associated with an increased risk of ovarian cancer recurrence [ 16 ]. HIPEC is a new type of chemotherapy based on the different tolerance of tumor cells and normal cells to temperature, and HIPEC causes irreversible damage to tumor cells at 43°C [ 17 ]. The HIPEC technique improves the activity of chemotherapeutic drugs, promotes the intertissue penetration of drugs, and interferes with the metabolism of tumor cells, which well inhibits ovarian cancer cells from developing distant metastases [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

[Retracted] Clinical Efficacy and Safety of Tumor Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Ovarian Cancer

2023

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To assess the clinical efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer. Methods. From April 2018 to November 2021, 66 patients with ovarian cancer were admitted to our hospital and randomly allocated to undergo intravenous chemotherapy following CRS (the observation group) or CRS with HIPEC (the experimental group) using a parallel randomized technique, with 33 cases in each group. Clinical effectiveness, intraoperative and postoperative recovery, VEGF level, T-lymphocyte subpopulation cell level, adverse events, and patient survival were all outcome metrics. Results. CRS plus HIPEC was associated with significantly higher clinical efficacy versus CRS alone ( P < 0.05 ). The difference in the intraoperative bleeding and operative time between the two groups did not meet the statistical standard ( P > 0.05 ). Patients in the experimental group experienced shorter postoperative chemotherapy and length of hospital stay than those in the observation group ( P < 0.05 ). CRS plus HIPEC resulted in significantly lower levels of VEGFA, VEGFB, and VEGFC and higher levels of CD3+, CD4+, and CD3+/CD4+ than CRS alone ( P < 0.05 ). The two groups of patients had a similar incidence of adverse events ( P > 0.05 ). The experimental group showed a longer median survival (25 months) and a 1-year survival rate (79.55%) than the observation group (22 months, 49.56%) (log rank = 20.411, P < 0.05 ). A significantly lower 1-year recurrence rate was observed in the experimental group than in the observation group ( P < 0.05 ). Conclusion. CRS plus HIPEC effectively improves the clinical efficacy of ovarian cancer patients, prolongs the survival of patients, and improves the level of VEGF and T-lymphocyte subpopulation cells, with a manageable safety. In addition, the treatment method can improve the therapeutic effect, reduce the toxic and side effects, and improve the immunity of the body, which is worthy of clinical promotion.

show abstract

Section: Discussionmentioning

confidence: 99%

[Retracted] Clinical Efficacy and Safety of Tumor Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Ovarian Cancer

2023

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…In several existing RCT studies, significant difference in adverse effects was not observed in the HIPEC and control groups [ 13 15 ]. Moreover, HIPEC does not appear to reduce health-related quality of life of patients, as shown in the KOV-HIPEC-01 study [ 29 ]. However, in another study, a significant increase in hypoalbuminemia, nausea, vomiting, and electrolyte disturbance was reported in the HIPEC group [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Ten-year treatment outcomes of consolidation hyperthermic intraperitoneal chemotherapy for ovarian cancer (HIPEC-KOV-03R)

et al. 2023

Self Cite

View full text Add to dashboard Cite

Objective We aimed to evaluate the long-term efficacy of consolidation hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with primary epithelial ovarian cancer. Methods This retrospective cohort study included patients who underwent second-look surgery either with or without HIPEC after having complete or partial response to primary cytoreductive surgery and adjuvant platinum-based chemotherapy between January 1991 and December 2003 at Seoul St. Mary’s Hospital. The 10-year progression-free survival (PFS), overall survival (OS), and toxicity within postoperative 28 days were investigated. Results A total of 87 patients were identified, 44 (50.6%) received second-look surgery with HIPEC whereas 43 (49.4%) received only second-look surgery. The 10-year PFS and OS were significantly longer in the HIPEC group compared with the control group (PFS, 53.6% vs. 34.9%, log-rank p=0.009; OS, 57.0% vs. 34.5%, log-rank p=0.025). Multivariable analysis identified HIPEC as an independent favorable prognostic factor for PFS (adjusted hazard ratio [HR]=0.42; 95% confidence interval [CI]=0.23–0.77; p=0.005) but not for OS (adjusted HR=0.58; 95% CI=0.32–1.07; p=0.079). The more common adverse events in the HIPEC group were thrombocytopenia (90.9% vs. 68.3%, p=0.005), elevated liver enzymes (65.9% vs. 29.3%, p=0.002), and wound complications (18.2% vs. 2.4%, p=0.032). However, these adverse events were reversible and did not delay subsequent consolidation chemotherapy. Conclusion The consolidation HIPEC demonstrated a significant improvement in 10-year PFS but not OS, with acceptable toxicity in patients with primary epithelial ovarian cancer. Further randomized controlled trials are warranted to confirm these results.

show abstract

“…Long-term quality of life in CRS/HIPEC patients has been a subject of debate. Several studies have demonstrated that the majority of patients return to baseline within one year of CRS/HIPEC [ 14 , 15 ]. The addition of HIPEC to CRS alone has also been shown to be safe [ 16 , 17 ].…”

Section: Discussionmentioning

confidence: 99%

Achieving Intraperitoneal Disease Control Using Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Two Cases of Metastatic Breast Cancer

Barakat¹,

Gushchin²,

Zuñiga³

et al. 2023

Cureus

View full text Add to dashboard Cite

Peritoneal metastases from breast cancer (PMBC) tend to occur late in the disease course and are challenging to manage. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) provide peritoneal disease control in other malignancies and may achieve similar results in PMBC. We assessed intraperitoneal disease control and outcomes in two PMBC patients after CRS/HIPEC. Patient 1, diagnosed at age 64, had hormone-positive/human epidermal growth factor receptor 2 (HER2)-negative lobular carcinoma treated with mastectomy. Prior to salvage CRS/HIPEC at age 72, five cycles of intraperitoneal chemotherapy via an indwelling catheter failed to control recurrent peritoneal disease. Patient 2, diagnosed at age 52, had hormone-positive/HER2-negative ductal-lobular carcinoma and received lumpectomy, hormonal therapy, and target therapy. Prior to salvage CRS/HIPEC at age 59, she had recurring ascites that was resistant to hormonal therapy and required multiple paracenteses. Both underwent complete CRS/HIPEC with melphalan. The only major complication was anemia, which required a transfusion in both patients. They were discharged on postoperative days 8 and 13, respectively. Patient 1 had peritoneal recurrence 26 months post-CRS/HIPEC and died of disease at 49 months. Patient 2 never had peritoneal recurrence and died of extraperitoneal progression at 38 months. In conclusion, CRS/HIPEC is safe and can provide intraperitoneal disease and symptom control in select patients with PMBC. Thus, CRS/HIPEC can be offered to these rare patients who have failed standard treatments.

show abstract

Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)

Cited by 22 publications

References 30 publications

[Retracted] Clinical Efficacy and Safety of Tumor Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Ovarian Cancer

[Retracted] Clinical Efficacy and Safety of Tumor Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Ovarian Cancer

Ten-year treatment outcomes of consolidation hyperthermic intraperitoneal chemotherapy for ovarian cancer (HIPEC-KOV-03R)

Achieving Intraperitoneal Disease Control Using Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Two Cases of Metastatic Breast Cancer

Contact Info

Product

Resources

About